GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Daxor DXR · USD

Health Care · US listing · 🇺🇸 United States

Compare

8.72

+3.20%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

6 analysts, 1 Nov 2026. The analysts' own views, not ours.

  • 1Strong buy
  • 4Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 21 Feb 2026. Not our view.

Average target 23.80

Low
22.22
Average
23.80
Median
23.46
High
26.25

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$9.3m$16.4m$14.0m$29.2m$50.3m
Revenue, highest$9.3m$16.4m$14.0m$29.2m$50.3m
Revenue, lowest$9.3m$16.4m$14.0m$29.2m$50.3m
Earnings per share-0.21-0.030.401.001.80
Earnings per share, highest-0.21-0.030.401.001.80
Earnings per share, lowest-0.21-0.030.401.001.80
Analysts11111

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q2 2025
Forecast-0.06-0.11
Reported-0.66-0.07
Difference-1000.0%+32.5%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth — a year over 10 years. Return on equity 20.0%.

Model fair value

146.05

From earnings 146.05, from revenue 66.23.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.